Novavax | NVAX - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Adma Biologics USD 232.29M 5.59M 2026-03
Agenus USD 35.32M 2.51M 2025-12
AstraZeneca USD 1.55B 73K 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Cassava Sciences USD 48.31M 0 2026-03
Geron USD 640.9M 2.54M 2026-03
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
MannKind USD 308.91M 1.07M 2026-03
Merck USD 2.47B 12.72M 2025-12
Minerva Neurosciences USD 1000 0 2024-09
Moderna USD 391M 2M 2025-09
Novartis USD 1.91B 60K 2026-03
Novavax USD 162.58M 106K 2025-12
Pfizer USD 5.7B 13M 2026-03
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
TG Therapeutics USD 155.31M 95K 2025-12